Market closed
Vir Biotechnology/$VIR
Vir Biotechnology shares are trading lower after the company announced preliminary data from a clinical study that may not have met investor expectations.
16 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vir Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Ticker
$VIR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
408
ISIN
US92764N1028
Website
VIR Metrics
BasicAdvanced
$747M
-
-$4.22
1.36
-
Price and volume
Market cap
$747M
Beta
1.36
52-week high
$14.45
52-week low
$4.95
Average daily volume
1.2M
Financial strength
Current ratio
6.79
Quick ratio
5.839
Long term debt to equity
8.447
Total debt to equity
8.447
Management effectiveness
Return on assets (TTM)
-23.49%
Return on equity (TTM)
-44.59%
Valuation
Price to revenue (TTM)
35.476
Price to book
0.72
Price to tangible book (TTM)
0.73
Growth
Revenue change (TTM)
-73.79%
Earnings per share change (TTM)
5.22%
3-year revenue growth (CAGR)
-79.22%
3-year earnings per share growth (CAGR)
-22.27%
What the Analysts think about VIR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
VIR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VIR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VIR News
AllArticlesVideos
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Business Wire·1 day ago
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Seeking Alpha·2 days ago
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vir Biotechnology stock?
Vir Biotechnology (VIR) has a market cap of $747M as of May 10, 2025.
What is the P/E ratio for Vir Biotechnology stock?
The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of May 10, 2025.
Does Vir Biotechnology stock pay dividends?
No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Vir Biotechnology dividend payment date?
Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vir Biotechnology?
Vir Biotechnology (VIR) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.